Clinical Trial Update: A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating single doses of Sativex (nabiximols) for treatment-induced mucositis in patients with head and neck squamous cell carci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Sativex (nabiximol)

Snippet

Sponsor: GW Pharmaceuticals Ltd | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: TERMINATED